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Lysyl hydroxylase 3 (LH3), encoded by Plod3, is the multi-
functional collagen-modifying enzyme possessing LH, hy-
droxylysine galactosyltransferase (GT), and galactosylhy-
droxylysine-glucosyltransferase (GGT) activities. Although
an alteration in type I collagen glycosylation has been impli-
cated in several osteogenic disorders, the role of LH3 in bone
physiology has never been investigated. To elucidate the
function of LH3 in bone type I collagen modifications, we
used a short hairpin RNA technology in a mouse osteoblastic
cell line, MC3T3-E1; generated single cell-derived clones sta-
bly suppressing LH3 (short hairpin (Sh) clones); and charac-
terized the phenotype. Plod3 expression and the LH3 protein
levels in the Sh clones were significantly suppressed when
compared with the controls, MC3T3-E1, and the clone trans-
fected with an empty vector. In comparison with controls,
type I collagen synthesized by Sh clones (Sh collagen) showed
a significant decrease in the extent of glucosylgalactosylhy-
droxylysine with a concomitant increase of galactosylhy-
droxylysine, whereas the total number of hydroxylysine resi-
dues was essentially unchanged. In an in vitro fibrillogenesis
assay, Sh collagen showed accelerated fibrillogenesis com-
pared with the controls. In addition, when recombinant LH3-
V5/His protein was generated in 293 cells and subjected to
GGT/GT activity assay, it showed GGT but not GT activity
against denatured type I collagen. The results from this study
clearly indicate that the major function of LH3 in osteoblasts
is to glucosylate galactosylhydroxylysine residues in type I
collagen and that an impairment of this LH3 function signif-
icantly affects type I collagen fibrillogenesis.
Collagens are a large family of extracellular matrix proteins
comprising at least 29 different genetic types (1, 2). Among
those types, fibrillar type I collagen is the most abundant pro-
tein, and it is the major structural component in most connec-
tive tissues, including bone. One of the critical steps in collagen
biosynthesis, which contributes to the functional integrity of
the tissues, is the post-translational modifications, including
the hydroxylation of specific proline (Pro) and lysine (Lys) res-
idues, glycosylation of specific hydroxylysine (Hyl)2 residues,
and the formation of covalent intermolecular cross-links.
Although several functions have been proposed for collagen
glycosylation, such as control of collagen fibrillogenesis (3–7),
cross-linking (8–14), remodeling (15–22), and collagen-cell
interaction (23, 24), the function is still not well defined due in
part to the lack of clear understanding in themechanism of this
modification.
In fibrillar collagens, glycosylation occurs at specific Hyl res-
idues by hydroxylysine galactosyltransferase (GT) (EC 2.4.1.50)
and galactosylhydroxylysine-glucosyltransferase (GGT) (EC
2.4.1.66) resulting in the formation of galactosylhydroxy-
lysine (G-Hyl) and glucosylgalactosylhydroxylysine (GG-
Hyl), respectively. Recently, these enzymatic activities were
found in the multifunctional enzyme lysyl hydroxylase 3
(LH3), one of the collagen-modifying enzymes in the LH
family, encoded by Plod3 (25–27).
The GT and GGT activities of LH3 were identified by mea-
suring the transfer of radiolabeled sugar moieties to Hyl resi-
dues in calf skin gelatin substrate (25, 27). The biological signif-
icance of the GGT activity of LH3 in the biosynthesis of
collagen types IV and VI has been demonstrated from the stud-
ies of LH3-deficient mice (28–30). In addition, defective GGT
activity resulting from four polymorphic nucleotides in the
non-coding region of Plod3was detected in a family with dom-
inant epidermolysis bullosa simplex (31, 32). In another recent
finding, twoheterozygousmutations in thePlod3 coding region
have been associated with a rare syndrome of congenital mal-
formations affecting several connective tissues and organs (33).
As for the GT activity of LH3, the data have been somewhat
conflicting, and the biological significance is still not clearly
understood. This activity could be performed by recently
reported novel enzymes, glycosyltransferase 25 domains 1 and
2 encoded by GLT25D1 and GLT25D2, respectively (34).
It has been reported that altered collagen glycosylation is
associated with bone disorders (35–42). However, the role of
LH3 in type I collagen modification and bone biology has not
been investigated.
To elucidate the function of LH3 for bone type I collagen, we
used an in vitro loss-of-function approach in a mouse osteo-
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blast-like cell line, MC3T3-E1 (MC), by generating single cell-
derived clones stably suppressing LH3. Type I collagen pro-
duced by the clones was analyzed for the extent of
modifications (e.g. GG-Hyl, G-Hyl, and free Hyl) and fibrillo-
genesis. In addition, recombinant LH3-V5/His fusion protein
was generated, and its enzymatic functionswere investigated by
means of a newly developed high performance liquid chroma-
tography (HPLC)-based glycosyltransferase activity assay.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions—MC subclone 4, a well
characterized nontransformed mouse osteoblast-like cell line
(43), was purchased from American Type Culture Collection
(CRL-2593). The cells were grown in -minimum essential
media (Invitrogen) containing 10% FBS (Invitrogen) and sup-
plemented with 100 units/ml penicillin G sodium and 100
g/ml streptomycin sulfate. 293 human embryonic kidney
(HEK) cells were purchased from Clontech. The cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen) with high glucose (4.5 g/liter) and the same supple-
ments as described above. Both cell lines were cultured in a 5%
CO2 atmosphere at 37 °C, and themediumwas changed twice a
week.
Expression of Plod Family, Glt25d1, andGlt25d2 inMCCells—
MC cells were plated at a density of 2  105 cells/35-mm
dish; after 48 h, total RNA was extracted with TRIzol reagent
(Invitrogen); and 2 g of total RNA was converted into
cDNA by using the Omniscript reverse transcriptase kit
(Qiagen, Valencia, CA). Quantitative real time PCR was per-
formed using the sequence-specific primers for LH1 (Plod1;
Applied Biosystems assay number Mm00599925_m1), LH2
(Plod2; Mm00478767_m1), LH3 (Plod3; Mm00478798_m1),
Glt25d1 (Glt25d1; Mm00600638_m1), and Glt25d2 (Glt25d2;
Mm00625070_m1). The reactions were prepared and analyzed in
triplicates by the ABI Prism 7000 Sequence detection system
(AppliedBiosystems,Fostercity,CA).ThemRNAexpression level
of LH3 relative to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Applied Biosystems assay number 4308313) was ana-
lyzed by the 2CTmethod (44).
Generation of Short Hairpin-expressing Plasmid Targeting
Plod3—The target sequences for suppression of Plod3 were
designed using the siDesign Center web site (Dharmacon RNAi
Technologies). The three highest ranked targets were selected
(si1, AGAAGGAAATGGAGAAATA (start position 956); si2,
CCACAAGGGTGTAGATTAT (2715); and si3, GAACA-
AAACAGGAAGGTAA (1897)) and converted into short hair-
pin oligonucleotide sequences specific for pSilencer2.1 vector
by the siRNA converter (Ambion, Austin, TX). This method
added BamHI and HindIII restriction site overhangs at the
5-end of the sense and antisense oligonucleotide, respectively,
to facilitate efficient directional cloning into the pSilencer vec-
tors. The two complimentary 55-mer oligonucleotides for each
target were ordered (Eurofins MWG Operon, Huntsville, AL)
and annealed in the annealing buffer (10 mM Tris, pH 7.5–8.0,
50mMNaCl, 1mMEDTA) according to the condition described
in the instructionmanual for pSilencer2.1 vector. The annealed
oligonucleotides were then ligated into the pSilencer2.1-U6/
neo vector (Ambion), linearized with BamHI and HindIII
restriction enzyme digestion, and transformed into bacterial
competent cells. The clones with 100% nucleotide sequence
accuracy (Eton Bioscience, Durham, NC) for each target (Sh1,
Sh2, and Sh3) were selected and tested for their suppression
efficiency by transient transfection into MC cells using
FuGENE 6 transfection reagent (Roche Applied Science). The
non-transfected MC cells and those transfected with the origi-
nal pSilencer2.1-U6/neo plasmid (empty vector (EV); encoding
a hairpin siRNA sequence not found in any genome database)
were used as controls. After 48 h, total RNA was extracted,
converted into cDNA, and analyzed for the expression of Plod3
by quantitative real time PCR as described above. The suppres-
sion efficiency among the different shRNA target sites was then
compared (in percent) relative to the controls.
Generation and Characterization of MC Single Cell-derived
Clones Stably Suppressing LH3—MC cells were transfected
with the selected pSilencer2.1-U6/neo-Plod3 plasmid by using
FuGENE 6 transfection reagent (Roche Applied Science). After
48 h, the transfected cells were trypsinized, plated at a low den-
sity, and maintained under constant selection with 400 g/ml
G418 sulfate (Mediatech, Inc., Manassas, VA). Several single
cell-derived short hairpin (Sh) clones were isolated by cloning
rings and maintained in -minimum essential medium, 10%
FBS, 100 units/ml penicillin, 100 g/ml streptomycin, and 400
g/ml G418 sulfate. The single cell-derived EV clones were
isolated and maintained in the same manner as described
above. The selected Sh clones were then characterized by
comparing the level of Plod3 expression with those of the EV
clone and the non-transfectedMC cells by using quantitative
real time PCR. Three to six Sh clones with different levels of
Plod3 suppression were then characterized for its effects on the
mRNA expression of LH1 (Plod1; ABI assay number
Mm00599925_m1), LH2 (Plod2; Mm00478767_m1), Glt25d1
(Glt25d1; Mm00600638_m1), and type I collagen 2 chain
(Col1A2; Mm00483888_m1). The effect on cell proliferation
was assessed by using the CellTiter 96 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium assay (Promega,Madison,WI) as repor-
ted previously (45).
Generation of Anti-mouse LH3 Antibody—Polyclonal rabbit
anti-mouse LH3 antibody was commercially generated (Bethyl
Laboratories, Inc., Montgomery, TX) by immunization with
the HPLC-purified, synthetic peptide corresponding to amino
acids 357–371 (FSAVKLVGPEEALSA) conjugated to keyhole
limpet hemocyanin. The agarose-bound peptide was used for
the affinity purification of the antibody from the hyperimmune
rabbit serum obtained from the immunized animal. The sensi-
tivity and specificity of the antibody was determined by West-
ern blot analysis of purified recombinant LH3-V5/His-tagged
protein as described below.
Immunoprecipitation and Western Blot Analysis—To deter-
mine the LH3 protein level, the Sh clones and the controls were
plated onto 35-mm dishes at a density of 3  105 cells/dish.
After culturing for 7days, the culturemediumwas collected; the
cells were washed with PBS, lysed with lysis buffer (150 mM
NaCl, 20mMTris-HCl, pH 7.5, 10mMEDTA, 1%Triton X-100,
1% deoxycholate, 1.5% aprotinin, and 1 mM phenylmethylsul-
fonyl fluoride), and centrifuged; and the supernatant was col-
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lected. The culturemediumwas incubated overnight with anti-
LH3 antibody (see above) followed by incubation with protein
G-Sepharose 4B-conjugated beads (Invitrogen) for 30 min,
washed with lysis buffer, solubilized in SDS sample buffer (100
mMTris-HCl, pH 8.8, 0.01% bromphenol blue, 36% glycerol, 4%
SDS) in the presence of 10 mM dithiothreitol, and separated by
a 4–12% NuPAGE Bis-Tris gel (Invitrogen). As for the cell
lysates, the total protein concentration was measured by the
DC protein assay kit (Bio-Rad) according to themanufacturer’s
protocol, and 20 g of total protein was directly applied to a
4–12% NuPAGE Bis-Tris gel. The separated proteins were
transferred to a polyvinylidene fluoride (PVDF) membrane
(Immobilon-P,Millipore Corp., Bedford,MA) and subjected to
Western blot analysis with anti-LH3 antibody followed by incu-
bation with anti-rabbit IgG conjugated to alkaline phosphatase
secondary antibody (Thermo Scientific, Rockford, IL). The
immunoreactivities were detected with alkaline phosphatase
conjugate substrate kit (Bio-Rad). Equal protein loading of cell
lysate was confirmed by Western blotting with anti--actin
antibody.
Purification of Type I Collagen—The same number of cells of
MC, EV, and Sh clones were plated onto 10-cm dishes and
maintainedwith twice-a-week change ofmedium (-minimum
essential medium, 10% FBS, 100 units/ml penicillin, 100 g/ml
streptomycin). When the cells reached confluence, 50 g/ml
ascorbic acid was added and cultured for at least 2 weeks, and
then the cell/matrix layer was collected and subjected to type I
collagen extraction as described previously (46). Briefly, the
cells/matrices were washed with PBS and cold distilled water,
lyophilized, and subjected to limited pepsin digestion (20%,
w/w) in 0.5 N cold acetic acid with constant stirring at 4 °C for
24 h. After ultracentrifugation at 35,000 rpm for 2 h, the super-
natant was collected, and type I collagen was precipitated with
0.7 M NaCl. The precipitate was then reconstituted with 0.5 N
acetic acid, dialyzed against cold distilled water for 48 h at 4 °C,
and lyophilized. Collagen solutionwas prepared by reconstitut-
ing the lyophilized collagen in 0.01 N acetic acid to a concentra-
tion of 0.5 g/l. The purity of type I collagen obtained from
the control cells and clones was assessed by 6% Tris-glycine gel
electrophoresis (Invitrogen) and staining with Coomassie Bril-
liant Blue (CBB) and by amino acid analysis (see below).
In Vitro Fibrillogenesis Assay—The procedure described pre-
viously (47) was slightlymodified for the use of a 96-wellmicro-
titer plate. Briefly, lyophilized type I collagen purified fromeach
groupwas redissolved in 0.01 M acetic acid at a concentration of
0.2 g/l. The reactions were prepared in triplicates in a
96-well microtiter plate (precooled on ice) containing the reac-
tion buffer (140 mM NaCl, 30 mM sodium phosphate (PBS) at
pH 7.3) (48) and purified type I collagen in a ratio of 1:1 (v/v)
and placed in a Powerwave X 340 spectrophotometer (BioTek,
Winooski, VT) equilibrated at 37 °C. Formation of collagen
fibrils was monitored by measuring the absorbance at 400 nm
(turbidity) at 1000-s intervals for 15 readouts. The turbidity-
time curve was plotted, and the differences in the rate of colla-
gen fibril formation and the potential fibril diameter among the
clones and the controls were compared.
Purification of GG-Hyl and G-Hyl Standards—Natural
marine sponge was used to isolate GG-Hyl residues (49, 50).
Fifty milligrams of sponge was pulverized in a Spex freezer mill
(SPEX CertiPrep, Metuchen, NJ), subjected to base hydrolysis
with 2 N NaOH in sealed polypropylene tubes flushed with N2
gas, and incubated at 110 °C for 22 h. The hydrolysate was acid-
ified to pH 3 with 2 N HCl and filtered. It was then applied to
a standardizedmolecular sieve column filled with Bio-Gel P-2
resin (Bio-Rad) equilibrated in 0.1 N acetic acid buffer at a flow
rate of 0.7ml/min andmonitored by absorbance at 214 nm (51).
Several collagen cross-link standards were used as molecular
weight standards to isolate the GG-Hyl (molecular mass, 487
Da)-enriched fractions. The GG-Hyl residues eluted slightly
earlier than the pyridinoline standard (molecular mass, 428
Da). To generate the monoglycosylated form, G-Hyl, the puri-
fied GG-Hyl was subjected to mild acid hydrolysis with 0.8 N
HCl at 110 °C for 1 h. The resulting G-Hyl was purified using
the P-2 column as described above. The identities of the puri-
fied GG-Hyl and G-Hyl were confirmed by mass spectrometry.
Mass Spectrometry Analysis of Glycosylated Hydroxylysine
Standards—The fraction containing GG-Hyl, G-Hyl, and free
Hyl from themild acid hydrolysis was analyzed by nanoelectro-
spray ionization-MS on aWaters QTof Global mass spectrom-
eter (Milford, MA). A 1:100 dilution (v/v) in a solvent mixture
containing 50% methanol in deionized water acidified with
0.1% formic acid was used for flow injection analysis. The mass
spectra were acquired over the mass rangem/z 150–1000. The
source parameters used were as follows: capillary voltage, 3.5
kV; cone voltage, 80 V; collision energy, 10 V. The MS/MS
spectra were acquired using targeted analysis of the ions of
interest. The collision energy was optimized for each ion, rang-
ing from 10 to 15 V for the singly protonated ion of G-Hyl and
from 15 to 25 V for the singly protonated ion of GG-Hyl.
Quantification of GG-Hyl, G-Hyl, and Free Hyl—Lyophilized
collagen samples were hydrolyzed with 6 N HCl (Sequenal
grade; Thermo Scientific) in vacuo after flushing with N2 at
110 °C for 22 h. The hydrolysates were subjected to amino acid
analysis on a Varian 9050 HPLC system (9050/9012; Varian
Associates Inc., Palo Alto, CA) equipped with a strong cation
exchange column (AMINOSep catalog number AA-911,
Transgenomic, Omaha, NE) (46). The level of total Hyl (GG-,
G-, and freeHyl) in a collagenmoleculewas calculated based on
the value of 300 residues of Hyp per collagen molecule.
To determine the level of glycosylated Hyl, lyophilized colla-
gen samples were also subjected to base hydrolysis, and the
hydrolysates were prepared in the same manner as described
above. Then the GG-Hyl, G-Hyl, and free Hyl in the hydroly-
sates were separated and quantified with a specific gradient
program (see Table 1) developed on the same HPLC system
mentioned above. Separation of the different Hyl species from
one another and from other amino acids was achieved in 75
min. The color factor of Hyl was used to calculate the quantity
of GG-Hyl and G-Hyl (52–54). Because Hyp is partially
degraded during base hydrolysis, the amount of total Hyl/col-
lagen was determined by acid hydrolysis (see above). Based on
the ratio of the three Hyl forms (GG-, G-, and free Hyl) and the
total Hyl values obtained from acid hydrolysis, each form ofHyl
was quantified as residues/collagen molecule.
Molecular Cloning of Mouse LH3 cDNA—Total RNA was
isolated from MC cells using TRIzol reagent (Invitrogen)
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according to the manufacturer’s protocol. The first strand
cDNAwas synthesized from 2 g of total RNA bymeans of the
Omniscript reverse transcriptase kit (Qiagen). Specific primers
for the coding sequence of mouse LH3 (GenBankTM accession
NM011962) were designed as follows: forward primer, includ-
ing restriction enzyme sequence for EcoRI, 5-GCGAATTC-
CGGGCCTGGGTGTAGCCT-3; reverse primer, including
the sequence for XhoI, 5-GCCTCGAGGGGGTCAACAA-
AGGACACCATG-3. PCRamplificationwas performedby the
ProofStart DNA polymerase (Qiagen) with an annealing tem-
perature of 60.0 °C for 40 cycles. After digesting the PCR
products with EcoRI and XhoI restriction enzymes, the inserts
were ligated into the pcDNA3.1/V5-His-TOPO_verA vector
(Invitrogen) generating the pcDNA3.1/LH3/V5-His con-
structs. The orientation and molecular size of the ligated insert
of 2389 bpwere analyzed by EcoRI andXhoI restriction enzyme
digestion followed by 2% agarose gel electrophoresis. Plasmids
containing digested inserts were sequenced at the University of
North Carolina at Chapel Hill DNA Sequencing Facility and
showed 100% homology to the mouse LH3 in the database.
Purification of LH3-V5/His Fusion Protein—293 HEK cells
were transfected with pcDNA3.1/LH3/V5/His vector using
FuGENE 6 transfection reagent (Roche Applied Science)
according to themanufacturer’s instructions, and the cells were
cultured in the presence of 400g/mlG418 sulfate (Mediatech,
Inc.) to isolate stably transfected single cell-derived clones.
Based onWestern blot analysis with anti-V5-alkaline phospha-
tase antibody, the clone that synthesized the highest level of
LH3-V5/His protein was selected and cultured to collect the
culturemedium. LH3-V5/His proteinwas purified using a nick-
el-nitrilotriacetic acid-agarose resin (Qiagen) and eluted with
elution buffer containing 0.2 M NaCl, 0.1 M glycine, 0.1% glyc-
erol, 50 mM urea, 20 mM Tris, and 0.05 M histidine, pH 7.5. The
purified proteins were pooled, dialyzed, concentratedwith cen-
trifugal filter with molecular weight cutoff 30,000 (Centricon,
Millipore Corp.), and stored at 20 °C until use. The protein
concentration was measured using a DC protein assay kit (Bio-
Rad), and the purity of the purified LH3-V5/His protein was
determined by a 4–12% NuPAGE Bis-Tris gel and CBB stain-
ing. To confirm its identity, the gel-resolved proteins were
transferred to a PVDF membrane (Immobilon-P, Millipore
Corp.) and subjected to Western blot analysis with anti-V5-
alkaline phosphatase antibody (Invitrogen) or anti-LH3 anti-
body (Bethyl Laboratories, Inc.). The identity of the LH3-V5/
His protein band and the specificity of the anti-LH3 antibody
were confirmed by an immunizing peptide blocking experi-
ment. Anti-LH3 antibody was preincubated with a 15, 30, or
60-fold molar excess of the blocking peptide (CFSAVKLVG-
PEEALSA) for 30 min prior to immunoblotting. The immuno-
reactivities were detected as described above.
HPLC-based Collagen Glycosyltransferase Assays—Pep-
sinized bovine skin collagen solution (PureCol, 3 mg/ml) was
purchased fromAdvanced BioMatrix (Tucson, AZ). Denatured
collagen substrate was prepared by incubating the PureCol
solution in distilledwater at 60 °C for 30min and rapidly cooled
on ice before use. The PureCol solution without heat denatur-
ation was used as a native collagen substrate. The assay for GT
or GGT reaction was performed in precooled 0.65-ml micro-
centrifuge tubes containing 120 g of native or denatured col-
lagen substrate, 60 M UDP-Glc or UDP-Gal (Calbiochem/
EMDChemicals, Gibbstown, NJ), 12 l of reaction buffer (16.7
mM MnCl2, 1 mM DTT, 2 mg/ml BSA, 0.1 M sodium bicarbon-
ate buffer, pH 7.8), recombinant LH3-V5/His protein (1%
(w/w) of collagen substrate), and distilled water in a total vol-
ume of 100 l. The tubes were incubated at 37 °C for 45 min,
and the reactions were terminated by placing the tubes on ice.
The dose effects of recombinant LH3-V5/His protein on GT
and GGT activities were evaluated using three concentrations
of the protein, i.e. 1, 3, and 5% (w/w of collagen substrate). The
reaction products were dried by speed vacuum centrifugation
(Savant Instrument Inc., Hicksville, NY), hydrolyzed with base,
and analyzed for the level of GG-Hyl, G-Hyl, and free Hyl as
described above.
Statistical Analyses—Statistical analyses were performed
using Jmp8.0 software (SAS Institute Inc., Cary, NC). Statisti-
cal differences were determined by Kruskal-Wallis one-way
analysis of variance and mean comparison with the controls by
Dunnett’s method. The data were presented as means  S.D.,
and a p value less than 0.05 was considered significant.
RESULTS
Expression of Plod Family, Glt25d1, andGlt25d2 inMCCells—
At 48 h of MC cell culture, the expressions of Plod1–3 and
Glt25d1–2 were analyzed by quantitative real time PCR. By
normalizing to GAPDH, the results showed that Plod3 was
expressed at the highest level among the Plod family. In addi-
tion, Glt25d1 was highly expressed in MC cells, whereas
Glt25d2was undetectable (Fig. 1). The expression of Plod3 and
Glt25d1 remained high, and that of Glt25d2 was undetectable
up to 4 weeks of culture (data not shown). Among these genes,
the highest expression was consistently observed for Plod3.
Generation of Clones Stably Suppressing Plod3—By tran-
siently transfecting MC cells with pSilencer2.1-U6/Neo plas-
mids encoding hairpin oligonucleotides targeting three differ-
ent sites in Plod3, the expression levels of Plod3 relative to
GAPDH from all three targets were significantly suppressed. In
comparison with the non-transfected MC cells (100%), the
expression levels of Plod3 in Sh1, Sh2, and Sh3 were 20, 22, and
46%, respectively. The Plod3 expression in the transfected con-
trol (EV) was 80% of that of MC cells. The suppression levels
FIGURE 1. Gene expression of Plod and Glt25 families in MC cells. After 48 h
of culture of MC cells, the mRNA expression of Plod1, Plod2, Plod3, Glt25d1,
and Glt25d2 relative to internal control (GAPDH) was analyzed by quantitative
real time PCR. Note that the expression of Plod3 is the highest among all the
genes, and only Glt25d1, but not Glt25d2, is expressed in MC cells. Error bars
indicate mean  S.D. of three independent experiments.
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of Plod3 among the different targeting sequences were essen-
tially the same when normalized to Col1A2 (data not shown).
Targeting sequence 1 (Sh1), showing themost suppression, was
selected to generate single cell-derived clones stably suppress-
ing LH3 by constant selection with G418 sulfate. Several clones
were isolated and characterized.
Characterization of Sh1-derived Clones Stably Suppressing
LH3—Three representative clones (Sh1-1, -2, and -3) stably
suppressing Plod3 that exhibited cell proliferation patterns
similar to that of controls were selected for further character-
ization. Quantitative real time PCR analyses from three inde-
pendent experiments showed statistically significant decreases
in the expression of Plod3 in all Sh clones (p  0.0001) com-
pared with the EV andMC controls (Fig. 2). The higher expres-
sion of Plod3 in the EV clone compared with the MC parental
cell was consistently observed during the isolation and charac-
terization of the EV clones, likely due to the effect of transfec-
tion. The effect of Plod3 suppression on the expression of the
other Plod family members and Glt25d1 was also investigated.
When normalized to GAPDH, the expressions of Plod2 and
Glt25d1 were not significantly changed in all three Sh clones
when compared with the controls. Plod1 expression was also
mostly unaffected except for Sh1-1 in that the expression of
Plod1was slightly lowerwhen comparedwith EV (p 0.05) but
not significantly different from that in MC.
The LH3 protein levels from the clones were assessed by
directWestern blot analysis for the cell lysate and immunopre-
cipitation/Western blot analysis for the culture medium (Fig.
3). In Fig. 3A, an immunoreactive band was observed at the
expected molecular mass of LH3 at 87 kDa in the cell lysates
of the controls and the Sh clones; however, the intensity was
decreased in all Sh clones. Comparable loading amounts of the
cell lysates were confirmed by Western blotting detection of
-actin. Fig. 3B shows the result of immunoprecipitation fol-
lowed by Western blot analysis with anti-LH3 antibody from
the culturemedia collected from the clones and controls. Com-
paredwith the controls, all three Sh clones showed lower inten-
sity of the immunoreactive bands observed at 91 kDa. The
apparent molecular mass of these bands was slightly higher
than those observed in the cell lysate (87 kDa). This observa-
tion is consistent with a previous report showing that the extra-
cellular LH3 protein is modified by asparagine-linked glycosyl-
ation during the secretion process (55). Together, these data
show that suppression of Plod3 by short hairpin RNA expres-
sion plasmid resulted in decreases in the levels of LH3 protein
both intra- and extracellularly.
Fibril Formation Kinetics of Purified Type I Collagen—Type I
collagen without telopeptides was purified from the 2-week
cell/matrix layer of the MC, EV, and Sh1-1, -2, and -3. The
purity of the collagens was determined by 6% Tri-glycine gel
electrophoresis where only the collagen-associated chains (
chains with some  and  components) were identified (data
not shown). In addition, amino acid analyses showed100Hyp
residues and 340 glycine residues/1000 amino acids in MC,
EV, and all the Sh clones, indicating a high level of collagen
purity. The purified collagen from the clones and controls was
subjected to an in vitro collagen fibrillogenesis assay to compare
the fibril formation kinetics among the groups. Fig. 4 shows the
turbidity-time curve plotted from the 400-nm absorbance
measured over time. Compared with the controls, MC, and EV,
the collagen from all three Sh clones showed a shorter lag time
and higher turbidity plateau, indicating a faster rate of fibril
formation and potentially larger collagen fibril diameter,
respectively (56).
Purification and Nanoelectrospray Ionization-Quadrupole
TOF Analysis of GG-Hyl and G-Hyl Standards—The GG-Hyl
and G-Hyl residues were purified from the base hydrolysate of
natural marine sponge by molecular sieve chromatography.
FIGURE 2. Gene expression of Plod family and Glt25d1 in single cell-de-
rived Sh clones. After 48 h of culture, real time PCR was performed to deter-
mine the suppression levels of Plod3 in the single cell-derived Sh clones and
its potential effects on Plod1, Plod2, and Glt25d1 expression. The mRNA
expression was normalized to the internal control (GAPDH). Error bars indi-
cate mean  S.D. of three independent experiments. *, significantly different
(p  0.0001) from MC and EV.
FIGURE 3. Levels of LH3 protein produced by Sh1-derived clones and con-
trols. A, Western blot analyses of cell lysates with anti-LH3 antibody and anti-
-actin antibody. Twenty micrograms of total protein from each sample was
loaded. B, immunoprecipitation-Western blot analyses of the culture media
with anti-LH3 antibody. The intensity of the immunoreactive bands from
Sh1-1, -2, and -3 was significantly lower than that of the controls, MC, and EV
in both cell lysate and culture media. WB, Western blotting; IP, immunopre-
cipitation; Ab, antibody.
FIGURE 4. In vitro fibrillogenesis assay. After 2 weeks of culture, type I col-
lagen without telopeptides was purified from the cell/matrix layers of MC cell,
Sh (1-1, 1-2, and 1-3), and EV clones. Twenty micrograms of purified collagens
(0.2 g/l) was incubated in a 96-well microtiter plate at 37 °C, and the
400-nm absorbance (turbidity) was measured (see “Experimental Proce-
dures” for details). The kinetics of the collagen fibrils formation are shown as
a turbidity-time plot.
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The identity of the purified GG-Hyl residues was indirectly
confirmed through the conversion of GG-Hyl into G-Hyl and
freeHyl bymild acid hydrolysis. Fig. 5A, upper panel, shows the
chromatogram of the potential GG-Hyl residue separated on a
strong cation exchange column and detected by the ninhydrin
derivatizationmethod. The programwas specifically developed
to separate GG-, G-, and free Hyl from one another and from
other known amino acids. The lower panel shows the same
compound after mild acid hydrolysis demonstrating a decrease
in the amount of the potential GG-Hyl and the appearance of
two additional ninhydrin-positive peaks eluting at later time
points. The double peak eluting at 70 min is consistent with
the elution of the Hyl standard. The double peak eluted at 47
min ismost likely the intermediate product in the conversion of
GG-Hyl into free Hyl, i.e.G-Hyl residue, based on the physico-
chemical characteristics of the molecule and previous reports
(50, 53, 57–58).
To confirm the identity, themild acid hydrolysate containing
a mixture of the potential three Hyl species was analyzed on a
QTof Global mass spectrometer by nanoelectrospray ioniza-
tion. The most abundant ion in theMS spectrum shown in Fig.
5B, observed as m/z 487.209 (1), was assigned to hydroxy-
lysinemodified with dihexose, GG-Hyl. The ion corresponding
to the G-Hyl species was observed asm/z 325.161. Unmodified
Hyl was observed as the singly protonated ion of m/z 163.105.
The structural characterization of each compound was per-
formed by MS/MS (shown in Fig. 5, C and D). The fragment
ions observed in theMS/MS spectrumof the ion ofm/z 487.209
(obtained with a collision energy of 20 V) are characteristic for
the collision-induced dissociation spectra of glycoconjugates,
confirming the structure GG-Hyl (Fig. 5C). The fragment ions
of m/z 325.165 and 163.103, assigned to Y1 and Y0 (59), are
derived from the subsequent neutral loss of each hexose from
the non-reducing end, whereas the ion ofm/z 367.178, assigned
to 0,2X1, resulted from a cross-ring cleavage in the first mono-
saccharide ring. The ion ofm/z 205.116 is most likely formed in
a secondary fragmentation event by cross-ring cleavage within
the Y1 fragment. This hypothesis is supported by the fact that,
by increasing the collision energy, this ion is observed with
higher relative abundance. The fragment ions observed in the
collision-induced dissociation spectrum of the ion of m/z
325.167 (shown in Fig. 5D) were obtained using a collision
energy of 15 V. The most abundant ion, m/z 163.101, Y0, is
derived from the fragmentation of G-Hyl from the non-reduc-
ing end.
Quantification of GG-Hyl, G-Hyl, and Free Hyl—To separate
and quantify the level of GG-Hyl, G-Hyl, and free Hyl, a new
program was developed on the amino acid analysis system in
our laboratory by modifying the buffer gradient (Table 1)
reported previously (46). The separation of the glycosylatedHyl
and the other amino acid standard is shown in Fig. 6. This
specific program can be used to analyze base hydrolysates of
FIGURE 5. Purification and identification of glycosylated Hyl standards. A, upper panel, ion exchange chromatogram of potential GG-Hyl residues isolated
from a P-2 column. Lower panel, ion exchange chromatogram of the same compound after mild acid hydrolysis, showing the conversion into free Hyl and an
intermediate product, potentially G-Hyl. B, mass spectrum of the mixture of Hyl, G-Hyl, and GG-Hyl from the amino acid analysis, showing the molecular ions
corresponding to each species. C and D, MS/MS spectra of the ions of m/z 487.221 and 325.167, confirming the structures of GG-Hyl and G-Hyl, respectively. CID,
collision-induced dissociation; mAU, milli-absorbance units.
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collagens as the carbohydrate units are retained under these
conditions. Fig. 7 shows the levels of the different Hyl species in
type I collagen purified from control cells and clones and ana-
lyzed in triplicates. The results revealed that there was a signif-
icant decrease in the level of GG-Hyl with a concomitant
increase in the level of G-Hyl in collagen from Sh clones,
whereas the levels of free Hyl remained comparable between
the Sh clones and the controls, MC, and EV. This modification
profile was also confirmed in type I collagen purified from the
other two independent sets of cultures. This clearly indicates
that themajor role of LH3 for type I collagen in osteoblasts is to
transfer glucose units to G-Hyl residues.
Purification of Recombinant LH3-V5/His Fusion Protein—
To confirm the glycosyltransferase activity of LH3, recombi-
nant LH3-V5/His fusion protein was purified from the culture
medium of 293 HEK cells. An aliquot from the collected frac-
tions was analyzed by a 4–12% NuPAGE Bis-Tris gel stained
with CBB and by Western blot analyses (Fig. 8). By CBB stain-
ing, a major single band was observed at 96 kDa consistent
with the expected molecular mass of LH3-V5/His fusion pro-
tein (91-kDa LH3  5-kDa tag). The identity of the purified
protein was further confirmed by Western blot analysis with
anti-V5 and anti-LH3 antibodies. In both cases, a single, immu-
noreactive96-kDa band was observed.When an immunizing
peptide blocking experiment was performed, even with a level
of 15-fold molar excess of peptide blocking, the immunoreac-
tivity of the protein to anti-LH3 antibody was almost com-
pletely abolished, indicating the competitive binding of the
peptides to anti-LH3 antibody. With higher concentrations of
the peptide, no immunoreactivity of the protein was observed
(data not shown). The fractions were then pooled, dialyzed, and
concentrated.
Glycosyltransferase Activity of LH3-V5/His Fusion Protein—
The results of the GT and GGT activity assays of LH3-V5/His
fusion protein with bovine skin collagen substrate are shown in
TABLE 1
Gradient system used for separation of GG-Hyl, G-Hyl, and free Hyl
Buffer A, 125 mM tartaric acid disodium, 172 mM maleic acid, 2.5% isopropyl alco-
hol, pH 2.78; Buffer B, 0.3 M NaOH, 107.7 mM maleic acid, 48.5 mM boric acid, pH
9.91.
FIGURE 6. HPLC elution profile of GG-Hyl, G-Hyl, and free Hyl relative to
other amino acids. The three-letter abbreviations are used to indicate amino
acids. mAU, milli-absorbance units.
FIGURE 7. Glycosylation levels of Hyl residues in purified type I collagen
synthesized by Sh1 clones and controls. The levels of GG-Hyl, G-Hyl, and
free Hyl are shown as residues/mol of collagen. Error bars indicate mean 
S.D. of triplicate analyses of the hydrolysates.
FIGURE 8. Characterization of recombinant LH3-V5/His-tagged protein.
Purified LH3-V5/His protein was subjected to a 4 –12% NuPAGE Bis-Tris gel,
staining with CBB, and Western blot (WB) analyses with anti-V5 antibody (V5),
anti-LH3 antibody (LH3), and anti-LH3 antibody with a 15-fold molar excess of
blocking peptide (LH3PB). The major band at the level of 96 kDa showed
immunoreactivities to both anti-V5 and anti-LH3 antibodies.
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Fig. 9. When LH3-V5/His fusion protein was incubated with
denatured collagen substrate, the level of GG-Hyl was signif-
icantly increased with a concomitant decrease in the level of
G-Hyl (Fig. 9A), leading to a reverse in the GG-Hyl/G-Hyl
ratio (Fig. 9B). However, the transfer of galactose units to
free Hyl was not observed as the GG-Hyl/G-Hyl ratio did not
change (Fig. 9B). When native bovine skin collagen was used
as a substrate, the GGT activity was not observed (Fig. 9, A
and B). To confirm the specificity of the enzymatic func-
tions, the dose effect of LH3-V5/His protein was examined
(Fig. 9C). With denatured collagen substrate, the change in
the GG-Hyl/G-Hyl ratio and the dose effect were observed
only for the GGT activity but not the GT activity. The GGT
activity was readily detected with an amount of LH3-V5/His
protein as low as 0.1% of the collagen substrate (w/w), indi-
cating a strong potency of the recombinant LH3-V5/His
fusion protein as an enzyme (data not shown). When native
collagen was used as a substrate, the GG-Hyl/G-Hyl ratio
was not changed with any levels of LH3-V5/His protein
examined (Fig. 9C). Similar results were observed when rat
tail tendon collagen was used as a substrate for the GT and
GGT activity assays (data not shown). The results shown
here indicate that the purified LH3-V5/His protein is enzy-
matically active with a specific function of glucosylation of
G-Hyl residues and suggest that the specific substrates for
LH3 are the collagen  chains rather than the native collagen
molecules, which is consistent with previous reports show-
ing that the triple helical conformation of collagens inhibited
further post-translational modifications (60, 61).
DISCUSSION
During the past decade, several reports have shown the
unique features of LH3, i.e. its multifunctionality (LH, GT,
and GGT activities) (25–27, 62) and its intra- as well as
extracellular localization (55). The critical importance of
this enzyme for connective tissue integrity was clearly dem-
onstrated through the gene knock-out mouse study and oth-
ers (29, 30, 32, 33). The enzymatic functions of LH3 were
shown through in vitro activity assays using lysates from SF9
cells transfected with LH3 expression plasmid, cell-free
translation, or purified recombinant LH3 protein as the
enzyme source (25–27, 62). The GGT activity of LH3 and its
biological significance have been well demonstrated; how-
ever, data regarding the GT activity of LH3 have been some-
what conflicting (25, 27, 28). Recently, Schegg et al. (34)
have reported the cloning of novel collagen galactosyltrans-
ferase enzymes GLT25D1 and GLT25D2 and showed that
these enzymes were capable of transferring galactose units to
free Hyl residues in collagen, whereas LH3 was not. How-
ever, direct measurements of the amount of G-Hyl or GG-
Hyl residues were rarely performed in the assays used in the
past. In this study, we successfully purified the G-Hyl and
FIGURE 9. HPLC-based glycosyltransferase activity assays of recombinant LH3-V5/His against denatured and native type I collagen. The transfer of
galactose to Hyl (GT activity) or glucose to galactosyl-Hyl (GGT activity) in type I collagen by recombinant LH3-V5/His protein was performed with denatured
and native bovine skin collagen (PureCol) substrate. The levels of free Hyl, G-Hyl, and GG-Hyl in collagen were determined by HPLC as shown in Fig. 6.
A, percentages of Hyl, G-Hyl, and GG-Hyl of total Hyl in the collagen substrate before (PureCol) and after the reaction for GT and GGT activities using LH3-V5/His
protein (1% (w/w) of collagen substrate). *, p  0.05 compared with control (PureCol). B, GG-Hyl/G-Hyl ratios calculated from A. *, p  0.05 compared with
control (PureCol). C, GG-Hyl/G-Hyl ratios from the GGT and GT activity assays using increasing levels of LH3-V5/His proteins (1, 3, and 5% (w/w) of collagen
substrate) with denatured or native collagen substrate. *, p  0.05 between the two groups indicated by a bracket. LH3, LH3-V5/His protein. Error bars indicate
mean  S.D. from each assay done in triplicate. *, significant difference (p  0.05).
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GG-Hyl standards from natural marine sponge and devel-
oped a specific HPLC program that allowed us to effectively
separate and quantify the levels of GG-Hyl, G-Hyl, and free
Hyl residues in the base hydrolysate of the collagen samples.
Type I collagen is the major collagen type in most connec-
tive tissues, including skin, bone and tendon. However, little
is known about the role of LH3 in this major fibrillar collagen
at present. In this study, by using the short hairpin RNA
technique in mouse osteoblasts, we successfully generated
single cell-derived clones stably suppressing LH3 and char-
acterized its effect on type I collagen post-translational mod-
ifications. Our data demonstrated that the major function of
LH3 is to glucosylate G-Hyl residues in type I collagen. The
simultaneous increase in the level of G-Hyl residues ob-
served from the LH3 Sh clones is most likely the result of a
diminished level of glucose transfer by LH3 suppression. The
gene expression of GLT25D1, another potential galactosyl-
transferase, was unaffected by LH3 suppression. In addition,
the levels of free and total Hyl residues in the purified type I
collagen were essentially unchanged among the Sh clones
and controls, suggesting that the LH activity of LH3, if any, is
minimal for bone type I collagen. In the past years, several
groups have tried to determine the sequence or collagen type
specificity for the activities of LH isoforms (28, 29, 63–70).
The results from these studies indicated that there are no
strict collagen types or sequence requirements for the indi-
vidual LH isoforms. It was suggested that LH2b, the major
isoform of LH2 in bone, mainly hydroxylates Lys residues in
the telopeptide regions, thus determining the collagen cross-
linking pathway (65, 67, 71–73). In contrast, LH1 preferen-
tially catalyzes the hydroxylation of Lys residues in the triple
helical region of fibrillar collagen, including those residues
pairing with the telopeptidyl Hyl/Lys aldehydes to form the
intermolecular cross-links (29, 65, 66, 68, 74). As for LH3, its
contribution to Lys hydroxylation in the helical region of
fibrillar collagen is still unclear (28, 29, 65). When the func-
tion of one isoform is impaired, compensatory mechanisms
from the other two isoforms may occur and may depend
largely on the tissue-specific expression of each isoform (70).
In this study, the enzymatic function of LH3 as the main
GGTbut notGTwas also confirmed by using the enzymatically
active recombinant mouse LH3-V5/His fusion protein gener-
ated by 293HEK cells culture. By usingHPLC,we could directly
measure the levels of GG-Hyl and G-Hyl in the reaction prod-
ucts of the GGT and GT activity assays. The specificity of the
glucosylation activity of LH3-V5/His protein against denatured
type I collagen was demonstrated by the dose -dependent
increase of GG-Hyl when increasing amounts of LH3-V5/His
protein were used. Furthermore, no transfer of galactose was
observed even with increasing amounts of LH3-V5 protein.
This result is consistent with studies showing that theGT activ-
ity of LH3 protein is very low (25, 27) or even undetectable (28,
34) in contrast to the GGT activity. As for the expressions of
Glt25d1 and -2, only the former isoform was detected in MC
cells. From our results and those recently reported by Schegg et
al. (34), it is likely that galactosylation of Hyl in bone type I
collagen is catalyzed by protein followed by subsequent gluco-
sylation by LH3.
The ability of recombinant LH3 to modify extracellular pro-
teins (collagen or other proteins) as shown by the GGT activity
assay indicated that LH3, unlike LH1 and LH2, is localized and
functional in the extracellular space as well (55). However, the
specific substrates for the extracellular function of LH3, such as
collagens or proteins with collagenous sequences, have never
been identified but were assumed to be collagen. Interestingly,
this finding contradicts with the earlier reports that triple heli-
cal conformation inhibits further modifications (60, 61). Thus,
it was proposed that at physiological temperature there is a
possibility of micro-unfolding of the triple helix, which allows
further modifications (55). In our study, when native bovine
skin collagen was used as a substrate for the GGT activity assay,
an increase in the level ofGG-Hylwas not observed as seenwith
denatured collagen substrate. This finding could suggest that
the specific substrate for the enzymatic function of extracellular
LH3 may not be type I collagen or that the secreted LH3 may
play a different role.
From the current study, it is apparent that a decrease in glu-
cosylation of G-Hyl in type I collagen significantly affects the
collagen fibril formation kinetics observed in the in vitro fibril-
logenesis assay. The collagen molecules with less glucosylation
could self-aggregate faster and form thicker fibrils due in part to
lesser steric hindrance for the molecular packing. This result is
consistent with other reports showing that the degree of colla-
gen modification is inversely correlated to the rate and diame-
ter size of collagen fibrils formed in vitro (3, 7, 75).
It has been shown that one of the major cross-linking sites in
the helical region of type I collagen (residue 87 of 1 and 2
chains) is mainly diglycosylated (8–10, 76–79). Thus, further
studies are warranted to investigate the potential effects of the
pattern (di- versusmonoglycosylation) and extent of glycosyla-
tion on cross-link formation and maturation.
Taken together, the results of this study show that, bymanip-
ulating the LH3 gene expression in mouse osteoblasts, the
major function of LH3 is to transfer glucose units to G-Hyl
residues in the  chains of bone type I collagen. This result was
also corroborated with the HPLC-based glycosyltransferase
activity assays using recombinant LH3-V5/His fusion protein.
The significant decrease in the transfer of glucose units,
through LH3 suppression, results in the change in the in vitro
collagen fibril formation kinetics. It can be concluded that the
levels and types of Hyl glycosylation and possibly its loci in type
I collagen are indeed critical for proper formation of collagen
fibrils.
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and Myllylä, R. (2000) J. Biol. Chem. 275, 36158–36163
26. Wang, C., Risteli, M., Heikkinen, J., Hussa, A. K., Uitto, L., and Myllyla, R.
(2002) J. Biol. Chem. 277, 18568–18573
27. Wang, C., Luosujärvi, H., Heikkinen, J., Risteli, M., Uitto, L., and Myllylä,
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